{"entity":{"id":"nct01674140","kind":"trial","name":"SWOG S1207 endocrine therapy with or without everolimus","aka":["S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer"],"tldr":"S1207 compares hormone therapy with or without everolimus after breast cancer treatment. It asks whether adding everolimus changes the chance of recurrence.","summary":"S1207 compares hormone therapy with or without everolimus after breast cancer treatment. It asks whether adding everolimus changes the chance of recurrence.\n\nInterventional study registered as NCT01674140, sponsored by SWOG Cancer Research Network. Registry phase: 3. Registry enrollment is 1,939 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT01674140","url":"https://clinicaltrials.gov/study/NCT01674140"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT01674140"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["anastrozole","everolimus","exemestane","goserelin","letrozole","tamoxifen"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01674140","phase":"3","setting":"Hormone receptor-positive, HER2-negative high-risk breast cancer after surgery","sponsor":"SWOG Cancer Research Network","participation":[{"nct":"NCT01674140","source":"https://clinicaltrials.gov/study/NCT01674140","fetchedAt":"2026-10-10T20:54:22.659395Z","studySha256":"896576439c3607f49fd6ded5cb247691ed7109a4286d041ce833a61783f953a4","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-02-10","leadSponsor":"SWOG Cancer Research Network","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1939,"enrolmentType":"ACTUAL","siteCount":1459,"recruitingSiteCount":0,"countries":["Puerto Rico","United States"]}],"started":"2013-09-12","startedType":"actual","enrolled":1939,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01674140/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/"},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}